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Abstract
We have developed a new method for assembling targeted nanoparticles that utilizes the
complexation between targeting agents that contain boronic acids and polymer-drug conjugates
that possess diols. Here, we report the first in vivo, antitumor results of a nanoparticle formed via
this new assembly methodology. A nanoparticle consisting of a mucic acid polymer conjugate of
camptothecin (CPT), MAP-CPT; and containing on average one Herceptin antibody is
investigated in nude mice bearing HER2 overexpressing BT-474 human breast cancer tumors.
Nontargeted MAP-CPT and antibody-containing MAP-CPT nanoparticles of ca. 30–40 nm
diameter and slightly negative zeta potential show prolonged in vivo circulation and similar
biodistributions after intravenous tail vein injections in mice. The maximum tolerated dose (MTD)
of the nontargeted and Herceptin-containing MAP-CPT nanoparticles are found to be 10 and 8 mg
CPT/kg, respectively, in mice. Mice bearing BT-474 human breast tumors treated with
nontargeted MAP-CPT nanoparticles at 8 mg CPT/kg show significant tumor growth inhibition
(mean tumor volume of 63 mm3) when compared to Irinotecan at 80 mg/kg (mean tumor volume
of 575 mm3) and CPT at 8 mg/kg (mean tumor volume of 808 mm3) at the end of the study.
Herceptin antibody treatment at 5.9 mg/kg results in complete tumor regressions in 5 out of 8
mice, with a mean tumor volume of 60 mm3 at the end of the study. Mice treated with MAP-CPT
nanoparticles at 1 mg CPT/kg do not show tumor inhibition. However, all mice receiving
administrations of MAP-CPT nanoparticles (1 mg CPT/kg) that contain on average a single
Herceptin molecule per nanoparticle (5.9 mg Herceptin equivalent/kg) show complete tumor
regression by the end of the study. These results demonstrate that the antitumor efficacy of
nanoparticles carrying anticancer drugs can be enhanced by incorporating on average a single
antibody.
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Introduction
Campthothecin (CPT) is a highly potent, naturally occurring anticancer alkaloid that acts by
inhibiting both topoisomerase I and HIF-1α activities.1,2 However, its systemic delivery is
problematic due to its low aqueous solubility and nonspecific toxicity. Under aqueous
conditions, CPT exists as either an active lactone form, that has anticancer properties, or as
an inactive carboxylate form, that has higher toxicity.3,4 The carboxylate form of CPT is
favored at physiological pH, and serum albumin preferentially binds to the carboxylate form
resulting in an equilibrium shift towards further CPT deactivation.5 The FDA approved CPT
derivatives Irinotecan (Camptostar™) and Topotecan (HycamptinTM) are used to treat solid
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tumors in a variety of cancers. However, the low percentages of the active form in
circulation, drug resistance and toxicity issues limit their clinical efficacy and
applications.6–9
A variety of polymers conjugated with CPT have been and are currently being evaluated in
clinical trials for the treatment of solid tumors.10–13 These molecular conjugates and
nanoparticles exploit the enhanced permeability and retention (EPR) effect that results in the
preferential accumulation of macromolecules in solid tumors.14 To increase cancer cell
uptake of nanoparticles that have reached the tumor site by the EPR effect, targeting ligands
against overexpressed or specific receptors on cancer cell surfaces can be placed on the
surfaces of the nanoparticles. These targeted nanoparticles are taken into tumor cells via
receptor-mediated endocytosis. Studies show that the targeted nanoparticles demonstrate
higher cellular uptake compared to their nontargeted nanoparticle counterparts with similar
sizes and surface charges.15–17
Antibody therapy has received wide attention due to its ability to selectively target tumor
cells through receptor-specific interactions.18 However, antibody therapy can rarely achieve
complete remissions, neither as a single agent, nor when used in combination with
chemotherapy.19,20 An example is Herceptin. (Trastuzumab), an antibody against HER2
(human epidermal growth hormone receptor 2) tyrosine kinase that is overexpressed in 20%
to 30% of breast cancers and is associated with resistance to therapy and a poor
prognosis.21,22 Herceptin is used in the clinic as a single agent after adjuvant chemotherapy,
or in combination with chemotherapy to treat HER2 overexpressing metastatic breast
cancers.23,24 Treatments containing Herceptin show better response compared to
chemotherapy alone. However, a significant proportion of patients treated in this manner
either do not respond or relapse after a period of clinical response.23,25,26
To improve the antitumor efficacy of antibody therapy, the selective tumor targeting
capability of an antibody can be combined with the cytotoxic ability of an anticancer drug
by the coupling of these two therapeutics to form an antibody-drug conjugate.27,28 The
antibody-drug conjugate brentuximab vedotin (Adcetris®) has been FDA approved to treat
Hodgkin's lymphoma and anaplastic large-cell lymphoma expressing the antigen CD30.29 It
is composed of an antibody specific for CD30 conjugated with approximately four
molecules of the antimicrotubule drug monomethyl auristatin E (MMAE).30 Treatment with
brentuximab vedotin alone in relapsed or refractory Hodgkin lymphoma patients resulted in
a complete response rate of 34%; in relapsed or refractory systemic anaplastic large-cell
lymphoma patients, it gave a complete remission rate of 57%.31,32 The recently FDA
approved antibody-drug conjugate, trastuzumab emtansine (Kadcyla®), is used for the
treatment of metastatic breast cancers and is comprised of a Herceptin antibody conjugated
with approximately three molecules of the cytotoxic emtansine.33 Patients with HER2
overexpressing metastatic breast cancers treated with trastuzumab emtansine show enhanced
clinical responses compared to those treated with lapatinib and capecitabine.34
While antibody-drug conjugate therapies show good clinical responses, they do not protect
their drug payload during circulation, they typically carry only two to four drug molecules
per antibody, and they have no ability to control the drug release kinetics.35 Nanoparticles
carrying anticancer drugs with antibodies on their surfaces can be used to protect and
increase the payload of the anticancer drugs. Additionally, drug release kinetics from the
nanoparticles can be tuned to provide a variety of behaviors. For instance, drugs (like CPT)
that interact with integral components of the cell cycle are best released over long periods of
time. This is to allow for long-term, effective intracellular drug concentrations since only a
fraction of the cells are cycling at any given time.
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Recently, antibody targeted nanoparticle delivery systems are increasingly being
investigated.36–39 In these formulations, there are many antibody molecules contained on the
surface of the nanoparticles. One question that has not yet been addressed is whether a
single-antibody molecule that is contained on the surface of the nanoparticle can affect the
properties of the nanoparticle. In other words, can a nanoparticle that contains one antibody
(a more close analogy to an antibody-drug conjugate) show functions of both the single
antibody and the nanoparticle? Additionally, can a single-antibody placed on a nanoparticle
containing anticancer drugs enhance its antitumor efficacy over the drug containing
nanoparticle analog? These are the questions that we begin to address here.
We have recently created a targeted nanoparticle delivery system for CPT through the
application of boronic acid-diol complexation.40 Hydrophobic CPT conjugated onto a
biocompatible hydrophilic copolymer of mucic acid and polyethylene glycol (MAP) self-
assembles into MAP-CPT nanoparticles. The antibody Herceptin is attached to the MAP-
CPT nanoparticle by the use of a boronic acid (via a polyethylene glycol (PEG) spacer).
This boronic acid-containing targeting moiety is then complexed with the diol-containing
MAP to form a targeted MAP-CPT nanoparticle (Scheme 1). We have shown that targeting
of MAP-CPT nanoparticles via a single Herceptin antibody is capable of achieving receptor
mediated uptake in BT-474 cells, a HER2 overexpressing human breast cancer cell line in
vitro.40 To date, no single-antibody targeted nanoparticle (that is, one antibody molecule per
nanoparticle) carrying anticancer drugs has been investigated in vivo. We therefore
examined the antitumor efficacies of nanoparticles that have on average a single antibody
versus nontargeted MAP-CPT nanoparticles in a mouse xenograft model to determine
whether a single-antibody on a nanoparticle can provide targeting in vivo.
Experimental Section
Materials
Breast carcinoma cell line BT-474 was purchased from American Type Culture Collection
(Manassas, VA). Cells were maintained in RPMI-1640 medium supplemented with 10%
fetal calf serum (Cellgro, Manassas, VA). Female BALB/c and NCr nude mice were
purchased from Jackson Laboratory (Bar Harbor, ME) and Taconic (Oxnard, CA)
respectively. 17β-estradiol pellets (0.72 mg, 90 day release) were purchased from Innovative
Research of America (Sarasota, FL). Herceptin® was obtained from Dr. Y. Yen at the City
of Hope (Duarte, CA). Campthothecin was purchased from Boehringer Ingelheim
(Ingelheim, Germany). Goat serum was obtained from Vector Laboratories (Burlingame,
CA). Rat anti-PEG primary antibody was purchased from AbCam (Cambridge, MA). Alexa
Fluor 488 goat anti-rat IgM secondary antibody, Alexa Fluor 633 goat anti-human IgG
secondary antibody and Prolong Gold Antifade reagent were obtained from Invitrogen
(Grand Island, NY). All other reagents were purchased from Sigma (St Louis, MO) unless
otherwise stated.
Medium MAP and nitroPBA-PEG (3-amide-PEG(5kDa), 5-nitrophenylboronic acid)
polymers; short, medium and long MAP-CPT nanoparticles; and Herceptin targeted MAP-
CPT nanoparticles were synthesized as previously described.40 Properties of polymers,
polymer-drug conjugates and nanoparticles used in this study are listed in Table 1.
HPLC Quantification of CPT
CPT concentrations were analyzed on a HPLC system (Agilent) equipped with a
fluorescence detector (excitation 370 nm, emission 440 nm) and a reverse phase column
(Synergi 4 μm Hydro-RP 80 Å, Phenomenex) complete with guard column. 50%
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acetonitrile, 50% potassium phosphate buffer (10 mM, pH 4) was used as the eluent at a
flow rate of 0.5 mL/min.
Animal Care
All animals were treated as per the National Institute of Health Guidelines for Animal Care,
and approved by the California Institute of Technology Institutional Animal Care and Use
Committee.
Pharmacokinetics
The nanoparticles formulated in 0.9 wt% NaCl (nontargeted nanoparticles) or PBS
(Herceptin targeted MAP-CPT nanoparticles) were administered via bolus, tail vein
injection into 12–16 week old female BALB/c mice. At predetermined time points, blood
was collected via saphenous vein bleed from individual mice with blood collection tubes
(Microvette CB 300 EDTA, Sarstedt). Samples were immediately centrifuged at 10,000 g, 4
°C for 15 min and supernatant was removed and stored at −80 °C until time for analysis.
Analyses for unconjugated and polymer-bound CPT were as follows. The amount of
unconjugated CPT was determined by first mixing 10 μl of sample with 10 μl of 0.1 N HCl
and incubating at room temperature for 30 min. 80 μl of methanol was then added and the
mixture incubated at room temperature for 3 h for protein precipitation. This mixture was
centrifuged at 14,000 g for 10 min at 4 °C, supernatant was filtered with a 0.45 μm filter
(Millex-LH), diluted 20 folds with methanol and 10 μl of the resulting solution was injected
into HPLC. The peak area of the eluted CPT (at 7.8 min) was compared to that of control
(known concentrations of CPT). To measure the total amount of CPT, 10 μl of sample was
mixed with 6.5 μl of 0.1 N NaOH. This solution was incubated at room temperature for 1 h
for CPT to be released from parent polymer. 10 μl of 0.1 N HCl was then added to convert
the carboxylate CPT form to the lactone form. 73.5 μl of methanol was subsequently added
and mixture incubated for 3 h at room temperature. The sample was then centrifuged and
processed as above. Polymer-bound CPT concentration was determined from the difference
between total CPT and unconjugated CPT concentrations. Non-compartmental modeling
software, PK Solutions 2.0 by Summit Research Services (Montrose, CO), was used for
pharmacokinetic data analysis.
Maximum Tolerable Dose (MTD)
12 week old female NCr nude mice were randomly divided into thirteen groups containing
five mice each. Medium MAP and nitroPBA-PEG polymers at 200 mg/kg; short MAP-CPT
nanoparticles at 10, 15 and 20 mg/kg (CPT basis); medium MAP-CPT nanoparticles at 8, 10
and 15 mg/kg (CPT basis); long MAP-CPT nanoparticles at 5, 8 and 10 mg/kg (CPT basis)
and the Herceptin targeted MAP-CPT nanoparticles at 8 and 10 mg/kg (CPT basis) were
administered on day 0 and day 7 via intravenous tail vein injections. All injections were
formulated in 0.9 w/v% saline except for the Herceptin targeted MAP-CPT nanoparticles
that were formulated in PBS, pH 7.4. Weight and health of the mice were recorded and
monitored daily for 2 weeks after the start of the treatment. MTD was defined as the highest
dose resulting in less than 15% body weight loss and with no treatment-related deaths.
Animals were euthanized when the criteria for the MTD was exceeded, or at the end of the
study by CO2 asphyxiation.
Biodistribution
7 week old NCr nude mice were transplanted subcutaneously with 17β-estradiol pellets.
After 2 days, BT-474 carcinoma cells suspended in RPMI-1640 medium were injected
subcutaneously into the front flank at 10 million cells/animal. Treatment began a day after
the tumors reached an average size of 260 mm3 (after 5 days). Animals were randomized
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into two groups of six mice per group and were treated via intravenous tail vein injections
with either MAP-CPT nanoparticles at 5 mg CPT/kg or Herceptin targeted MAP-CPT
nanoparticles at 5 mg CPT/kg and 29 mg Herceptin equivalent/kg (all formulated in PBS,
pH 7.4). After 4 h and 24 h, blood was collected from three animals from each group via
saphenous vein bleed. These animals were then euthanized by CO2 asphyxiation and
perfused with PBS. Tumor, lung, heart, spleen, kidney and liver were harvested and
sectioned into two approximately equal sized pieces. One piece was embedded in Tissue-
Tek® OCT (Sakura) and the other was collected in an Eppendorf tube. Samples were frozen
immediately at −80 °C until time for processing.
Organs were weighed and 100 mg of each were placed in Lysing Matrix A homogenizer
tubes containing an added ¼ inch ceramic spheres (MP Biomedicals, Solon, Ohio). 1 mL of
RIPA lysis buffer (Thermo Scientific) was added and tissues were homogenized using a
FastPrep®-24 homogenizer (MP Biomedicals, Solon, Ohio) at 6 m/s for 30 s. This was
repeated for 3 times with 1 min of cooling on ice in between each round. Samples were
centrifuged at 14,000 g for 15 min at 4 °C and supernatants were collected. The amount of
unconjugated CPT was determined by first mixing 10 μl of the supernatant with 10 μl of 0.1
N HCl and incubating at room temperature for 30 min. 80 μl of methanol was then added
and the mixture incubated at room temperature for 3 h for protein precipitation. This mixture
was centrifuged at 14,000 g for 10 min at 4 °C. Supernatant was filtered with a 0.45 μm
filter (Millex-LH) and 10 μl of the resulting mixture was injected into HPLC. The peak area
of the eluted CPT (at 7.8 min) was compared to that of control (known concentrations of
CPT). To measure the total amount of CPT, 10 μl of sample was mixed with 6.5 μl of 0.1 N
NaOH. This solution was incubated at room temperature for 1 h for CPT to be released from
its parent polymer. 10 μl of 0.1 N HCl was then mixed in to convert carboxylate CPT form
to lactone form. 73.5 μl of methanol was subsequently added and the mixture was incubated
for 3 h at room temperature. The sample was then centrifuged and processed as above.
Tumor Processing and Confocal Imaging
Tumors were sectioned using a cryostat into a thickness of 20–30 μm. The tumor sections
were placed on Superfrost Plus slides (Fisher Scientific, Hampton, NH) and stored at −80 °C
until time for further processing. Slides were defrosted and tissue sections were fixed onto
the slide for 15 min with a 10% formalin solution. The slides were washed with PBS and
blocked for 1 h in a 5% goat serum blocking buffer. A rat anti-PEG primary antibody (14
μg/mL) that recognizes the internal PEG units was placed on the slides and the slides were
incubated at 4 °C overnight. They were then washed with PBS and incubated for 1 h with
Alexa Fluor 488 goat anti-rat IgM secondary antibody (2 μg/mL). The slides were washed
with PBS and incubated for 1 h with Alexa Fluor 633 goat anti-human IgG secondary
antibody (2 μg/mL) to visualize Herceptin. They were washed one last time with PBS,
mounted with a Prolong Gold Antifade reagent and stored at 4 °C until time for imaging.
Images were acquired with a Zeiss LSM 510 Meta Confocal Microscope (Carl Zeiss,
Germany) using a 63× Plan-Neofluar oil objective. 2-Photon excitation at 720 nm (emission
filter BP 390–465 nm) was used to detect CPT. Excitation at 488 nm (emission filter LP
530) and at 633 nm (emission filter BP 645–700 nm) were used to detect PEG and Herceptin
respectively. All laser and gain settings were set at the beginning of the imaging and were
unchanged. Image analysis was performed with a Zeiss LSM image browser.
Antitumor Efficacy Studies
17β-estradiol pellets were transplanted subcutaneously into 7 week old NCr nude mice.
After 2 days, BT-474 human breast cancer cells suspended in RPMI-1640 medium were
injected subcutaneously into the front flank at 10 million cells/animal. Treatment began a
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day after tumors reached an average size of 250 mm3 (after 5 days). Animals were
randomized into nine groups of six to eight mice per group. MAP-CPT nanoparticles at 1
mg and 8 mg/kg (CPT basis, in PBS, pH 7.4), CPT at 8 mg/kg (in 20% DMSO, 20% PEG
400, 30% ethanol and 30% 10 mM pH 3.5 phosphoric acid), Irinotecan at 80 mg/kg (in 5 w/
v% dextrose solution, D5W), saline, Herceptin at 2.9 and 5.9 mg/kg (in PBS, pH 7.4),
Herceptin targeted MAP-CPT nanoparticles at 0.5 mg CPT/kg and 2.9 mg Herceptin
equivalent/kg, and 1 mg CPT/kg and 5.9 mg Herceptin equivalent/kg (in PBS, pH 7.4) were
freshly prepared and given via intravenous tail vein injections. Injections were standardized
at 150 μl per 20 g body weight of mice. Treatments containing Herceptin were given once
per week for 2 weeks. All other groups were given once per week for 3 weeks. Tumor sizes
were recorded thrice a week using caliper measurements (length × width2/2) and health of
the animals was continuously monitored. Animals were euthanized when tumor volumes
exceeded 1000 mm3. Six weeks after beginning of the treatment, all animals were
euthanized by CO2 asphyxiation.
When animals exited the study due to either tumor size exceeding animal protocol care
limits, or treatment-related or non-treatment-related deaths, the last tumor volume value
recorded was included in the subsequent data points presented. Two-tailed statistical
analyses were conducted at P = 0.05. Results were considered significant at 0.01 ≤ P ≤ 0.05
and highly significant at P < 0.01.
Results and Discussion
Pharmacokinetics
Plasma pharmacokinetic studies of short, medium, long MAP-CPT nanoparticles and
Herceptin targeted MAP-CPT nanoparticles at 10 mg/kg (CPT basis) injections were
conducted in female BALB/c mice (Fig. 1). Non-compartmental modeling was used for data
analysis (Table 2).
Plasma pharmacokinetics of the polymer-bound CPT for all nanoparticle formulations
displayed biphasic profiles with fast redistribution phases (α) and long elimination phases
(β) (Fig. 1A). The elimination phases for the medium and long MAP-CPT nanoparticles
were particularly prolonged with half-lives of 16.6 and 17.6 h, respectively, and showed
high AUC values of 2298 and 3636 μg.h/mL, respectively (Table 2). 24 h after injection,
11.3% of the injected dose of the medium MAP-CPT nanoparticles and 20.5% of the
injected dose of the long MAP-CPT nanoparticles were still circulating in plasma as
polymer-bound CPT (Fig. 1A). In addition, they exhibited small volumes of distribution and
low clearance rates. In contrast, male (BALB/c × DBA/2)F1 mice injected with CPT alone at
10 mg/kg showed fast clearance, with an AUC of only 1.6 μg.h/mL (Table 2, modified from
reference 41). Herceptin on the medium MAP-CPT nanoparticles affected their
pharmacokinetic profile by increasing the redistribution phase and prolonging the
elimination phase to 21.2 h with a high AUC value of 2766 μg.h/mL. The amounts of
unbound CPT in plasma for all nanoparticle formulations were low at all time points (Fig.
1B).
Maximum Tolerable Dose (MTD)
MTD values were defined as the highest dose resulting in less than 15% body weight loss
with no treatment-related deaths. Female NCr nude mice treated with medium MAP, the
nitroPBA-PEG polymer, the short, medium and long MAP-CPT nanoparticles, and the
Herceptin-containing MAP-CPT nanoparticles were weighed and monitored for health after
doses on day 0 and day 7 (Table 3 and Supplementary Fig. 1).
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The weight and health of the mice were unaffected by treatment at high doses of medium
MAP or nitroPBA-PEG polymers, indicating low toxicities for these polymeric components.
For groups containing CPT, maximum weight loss appeared 3 to 5 days after each treatment.
The majority of the groups gained back the lost weight. If body weight loss continued and
exceeded an average of 15%, then the study was concluded. Some mice in groups treated
with the medium MAP-CPT nanoparticles at 15 mg/kg and the long MAP-CPT
nanoparticles at 10 mg/kg showed diarrhea and appeared weak. All other mice appeared
healthy. MTD values were found to be 20, 10, 8 and 8 mg/kg (on CPT basis) for the short,
medium, long MAP-CPT nanoparticles, and the Herceptin-containing MAP-CPT
nanoparticles, respectively (Table 3).
Biodistribution
The percentage injected dose (ID) of total CPT per gram of tumor, heart, liver, spleen,
kidney and lung is shown in Fig. 2A. 4 h after dosing, 5.3 and 5.2% ID of total CPT were
present per gram of tumor in mice treated with MAP-CPT nanoparticles and Herceptin
targeted MAP-CPT nanoparticles, respectively. 24 h after treatment, 2.6% ID of total CPT
remained per gram of tumor for mice treated with MAP-CPT nanoparticles, while 3.2% ID
of total CPT were found per gram of tumor for mice receiving Herceptin targeted MAP-CPT
nanoparticles. These data show that targeting does not enhance the localization of
nanoparticles into the tumor site, and this result is consistent with literature
observations.15–17 Additionally, similar distributions of CPT in heart, liver, kidney and lung
were observed for nontargeted and targeted nanoparticles. There was, however, a significant
amount of total CPT accumulation in the spleen for Herceptin targeted MAP-CPT
nanoparticles compared to the nontargeted nanoparticles at 24 h. Significant accumulation in
the spleen has been observed previously for humanized antibodies in mice.42 Since the
Herceptin targeted nanoparticles show increased accumulation in the spleen compared to
that of the nontargeted nanoparticles, this result implies that during the biodistribution of the
Herceptin targeted nanoparticles, the Herceptin is remaining associated with the
nanoparticle.
Figure 2B shows the percentage of total CPT in each organ that is present in its
unconjugated form. The percentage of unconjugated CPT in heart, liver, spleen, kidney and
lung were low at both 4 h and 24 h. In the tumor at 24 h, there were significantly higher
percentages of unconjugated CPT for both MAP-CPT nanoparticles and Herceptin targeted
MAP-CPT nanoparticles compared to that at 4 h. The retention of unconjugated CPT within
the tumors suggests cellular accumulation of CPT. The Herceptin targeted nanoparticles
shows slightly higher percentage of unconjugated CPT in tumors compared to the
nontargeted nanoparticles at both 4 and 24 h.
The total concentration of CPT in plasma and the percentage of total CPT in plasma that is
present in its unconjugated form were similar for both MAP-CPT nanoparticles and
Herceptin targeted MAP-CPT nanoparticles (Fig. 2C). After 4 h, 17 and 20 μg/mL of total
CPT remained in plasma for MAP-CPT nanoparticles and Herceptin targeted MAP-CPT
nanoparticles, respectively. After 24 h, the amounts of total CPT remaining in plasma were
the same for both the MAP-CPT nanoparticles and Herceptin targeted MAP-CPT
nanoparticles (12 μg/mL). The percentages of total CPT in plasma that were unconjugated to
the polymer were below 3% for all conditions indicating fast clearance of unconjugated CPT
from plasma (Fig. 2D).
Confocal Imaging of Tumor Tissues
BT-474 tumor bearing NCr nude mice were treated with either MAP-CPT nanoparticles (5
mg CPT/kg) or the Herceptin targeted MAP-CPT nanoparticles (5 mg CPT/kg, 29 mg
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Herceptin equivalent/kg). After 4 and 24 h, mice were euthanized and tumors were removed
and processed for confocal, immunofluorescence imaging. CPT is intrinsically fluorescent
with excitation at 370 nm and emission at 440 nm. To identify the location of the MAP, the
PEG component within the MAP was first stained with an anti-PEG antibody; it was then
stained with a secondary antibody containing Alexa Fluor 488 (emission 519 nm). All tumor
sections were also stained for Herceptin with an anti-human IgG labeled with Alexa Fluor
633 (emission 647 nm). Images of the tumor section were taken at the same laser power and
gain settings. Representative images for each group are illustrated in Fig. 3.
Figure 3A shows tumor section of mice treated with MAP-CPT nanoparticles after 4 h. CPT
signal was disperse, and signals for CPT and MAP appeared to colocalize in the merged
image. 24 h after injection, there was accumulation of CPT signal in the form of punctate
spots, and the merged image suggests colocalization of CPT and MAP (Fig. 3B). For mice
treated with Herceptin targeted MAP-CPT nanoparticles, spots indicating CPT accumulation
were observed after both 4 and 24 h of treatment (Figs. 3C and 3D). In addition, there were
colocalizations of the CPT and the MAP signals in the merged images. The presence of
Herceptin in the Herceptin targeted MAP-CPT nanoparticles sample is indicated by the
strong blue signals in the Herceptin channel compared to the weak background signals in the
nontargeted version.
Antitumor Efficacy Studies
One of the most resistant breast cancer cell lines to anticancer drugs (including CPT) is
BT-474.43 We therefore chose this aggressive cell line to generate a tumor model to evaluate
the efficacy of our system. To promote tumor growth in nude mice, 17β-estradiol pellets
were implanted two days prior to BT-474 tumor cell implantation. On day 0 (5 days after
cell implantation), tumor sizes reached an average of 250 mm3. Treatments via intravenous
tail vein injections began on day 1. Irinotecan was administered at a dose of 80 mg/kg in 5
w/v% dextrose solution (D5W). CPT is highly insoluble in aqueous solutions, therefore, it
was dissolved in a solution containing 20% DMSO, 20% PEG 400, 30% ethanol and 30%
10 mM pH 3.5 phosphoric acid (a low pH was chosen to retain the CPT in its active lactone
form). A saline treatment group was used as the control. All other treatment groups were
administered in PBS at pH 7.4. Changes in tumor sizes were recorded by caliper
measurement thrice a week and the health of the animals was continuously monitored.
Five weeks after 17β-estradiol pellet implantations, several mice irrespective of treatment
groups showed distended bladder and abdominal bloating. This was likely due to the use of
17β-estradiol pellets, which is known to cause hydronephrosis and urine retention in athymic
nude mice.44 Six weeks after treatment, conditions became worse and more mice were
observed to develop distended bladders and abdominal bloating. These animals were
euthanized.
Tumors in the control group administered with saline grew rapidly (Fig. 4). After 28 days,
five out of the eight mice had tumors exceeding the size limit of 1000 mm3. All animals in
this group were euthanized at this time.
Animals treated with CPT (8 mg/kg) resulted in no tumor inhibition compared to that of the
control group (P > 0.05). One treatment-related death was recorded on day 9, and another
three were recorded on day 16. On day 28, four euthanizations were carried out due to tumor
sizes exceeding the size limit. None of the animals survived to the end of the study.
Mice treated with Irinotecan at 80 mg/kg showed non-significant tumor inhibition compared
to that of the control group (P > 0.05). One treatment-related death occurred on day 11.
Tumor sizes reached an average of 575 mm3 by the end of the study.
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Animals receiving MAP-CPT nanoparticles at 8 mg CPT/kg showed highly significant
tumor inhibition compared to that of the control group (P < 0.01). By the end of the study,
the mean tumor size was reduced to 63 mm3 from an initial average volume of 250 mm3.
Three out of the eight mice treated had complete tumor regression. Although no deaths
occurred in the MTD study using non-tumor bearing NCr nude mice treated with the MAP-
CPT nanoparticles at 8 mg CPT/kg, one death occurred in this study due to weight loss on
day 21. This death could be due to the effects of the added tumor burden and/or because
mice used in this study were 7 weeks old, while in the MTD studies, 12 week old mice were
used.
Animals treated with Herceptin at 5.9 mg/kg showed highly significant tumor inhibition
compared to that of the control group (P < 0.01). On day 11 of the treatment, seven out of
the eight animals treated showed significant tumor regression. However, by the end of the
study, two of the regressed tumors relapsed, resulting in a total of five animals with tumors
at zero volumes and a group mean tumor volume of 60 mm3 (Individual animal tumor data
are shown in Supplementary Fig. 2A).
The group treated with the MAP-CPT nanoparticles at 1 mg CPT/kg was terminated early
due to no observed antitumor effects.
When Herceptin at a dose equivalent of 5.9 mg/kg was added as a targeting agent via a
nitroPBA-PEG linker onto the MAP-CPT nanoparticles with a low CPT dose of 1 mg/kg
(Herceptin targeted MAP-CPT nanoparticles at 5.9 mg Herceptin equivalent/kg and 1 mg
CPT/kg), all tumors regressed to zero on day 9 of treatment and remained at zero by the end
of the study (individual animal tumor data are shown in Supplementary Fig. 2B). This result
is highly significant compared to that of the control group (P < 0.01). One non-treatment-
related death occurred on day 37. The combination of antitumor results observed for the
Herceptin at 5.9 mg/kg, the MAP-CPT nanoparticles at 1 mg CPT/kg and the Herceptin
targeted MAP-CPT nanoparticles (at 5.9 mg Herceptin equivalent/kg and 1 mg CPT/kg)
indicate that there is improved antitumor efficacy of the MAP-CPT nanoparticles due to the
incorporation of on average a single Herceptin targeting agent.
Animals treated with Herceptin at 2.9 mg/kg resulted in two animals having tumors
regressed to zero by the end of the study. The average tumor size increased from the
beginning of the study at 250 mm3 to 278 mm3 by the end of the study. This result is
significant compared to that of the control group (0.01 ≤ P ≤ 0.05).
When animals were treated with the Herceptin targeted MAP-CPT nanoparticles containing
0.5 mg CPT/kg and 2.9 mg Herceptin equivalent/kg, two tumors regressed to zero. The
average tumor size was reduced to 141 mm3 by the end of the study. This result is highly
significant compared to that of the control group (P < 0.01). The antitumor results from
animals treated with Herceptin at 2.9 mg/kg and the Herceptin targeted MAP-CPT
nanoparticles (at 2.9 mg Herceptin equivalent/kg and 0.5 mg CPT/kg) further indicate the
effectiveness of a nanoparticle that contains on average a single Herceptin.
Summary
Here, we report the in vivo behavior of a single-antibody targeted nanoparticle delivery
system. The targeted delivery of camptothecin (CPT) conjugated onto a mucic acid
containing polymer (MAP) was achieved by using a boronic acid-diol complexation
methodology with on average one Herceptin antibody per nanoparticle as the targeting
agent.40 Pharmacokinetics of both MAP-CPT nanoparticles and Herceptin targeted MAP-
CPT nanoparticles demonstrated prolonged circulation in vivo. Both nontargeted and
targeted nanoparticles showed similar biodistributions, except for increased accumulation of
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the targeted nanoparticle in the spleen that can be attributed to the antibody remaining
associated with the nanoparticle during its biodistributon. In mice bearing HER2
overexpressing BT-474 human breast cancer tumors, the effect of on average one Herceptin
antibody per MAP-CPT nanoparticle was sufficient to result in complete tumor regression,
as well as superior antitumor activity compared to that of the nontargeted MAP-CPT
nanoparticles and the Herceptin antibody alone groups. The roles of the antibody on the
nanoparticle were to alter the behavior of the nanoparticle within the solid tumor (Herceptin
can enhance BT-474 cell uptake) and to provide a therapeutic effect (Herceptin is active in
BT-474 cells).
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Refer to Web version on PubMed Central for supplementary material.
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Scheme 1.
Schematic of MAP-CPT nanoparticle and Herceptin targeted MAP-CPT nanoparticle
delivery systems. MAP = mucic acid and polyethylene glycol copolymer, CPT =
camptothecin, BA = boronic acid. Modified from ref. 40.
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Figure 1.
Plasma pharmacokinetics of short, medium and long MAP-CPT nanoparticles; and
Herceptin targeted MAP-CPT nanoparticles in female BALB/c mice at 10 mg CPT/kg
injections. (A) Plasma concentration of polymer-bound CPT as a function of time. (B)
Plasma concentration of unconjugated CPT as a function of time.
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Figure 2.
Biodistribution of MAP-CPT nanoparticles (5 mg CPT/kg) and Herceptin targeted MAP-
CPT nanoparticles (5 mg CPT/kg, 29 mg Herceptin equivalent/kg) after 4 and 24 h of
treatment in female NCr nude mice bearing BT-474 xenograft tumors. (A) Percent injected
dose (ID) of total CPT per gram of tumor, heart, liver, spleen, kidney or lung. (B)
Percentage of total CPT in each organ that is unconjugated in tumor, heart, liver, spleen,
kidney and lung. (C) Total concentration of CPT in plasma. (D) Percentage of total CPT that
is unconjugated in plasma.
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Figure 3.
Confocal immunofluorescence microscopy of BT-474 tumor sections taken from female
NCr nude mice treated with (A) MAP-CPT nanoparticles (5 mg CPT/kg) at 4 h (B) MAP-
CPT nanoparticles (5 mg CPT/kg) at 24 h. (C) Herceptin targeted MAP-CPT nanoparticles
(5 mg CPT/kg, 29 mg Herceptin equivalent/kg) at 4 h. (D) Herceptin targeted MAP-CPT
nanoparticles (5 mg CPT/kg, 29 mg Herceptin equivalent/kg) at 24 h. Left panel emission
440 nm (CPT, pink), center left panel emission 519 nm (MAP, green), center right panel
emission 647 nm (Herceptin, blue), right panel overlay of images.
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Figure 4.
Antitumor efficacy studies in female NCr nude mice bearing BT-474 xenograft tumors.
Mean tumor volumes as functions of time. Groups containing Herceptin received 2 weekly
doses, all other groups received 3 weekly doses.
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Table 2
Plasma pharmacokinetic parameters of polymer-bound CPT for short, medium and long MAP-CPT
nanoparticles; and Herceptin targeted MAP-CPT nanoparticles compared to CPT alone
t1/2α (h) t1/2β (h) AUC (μg.h/mL) Vd (mL) Cl (mL/h)
Short MAP-CPT nanoparticle 0.6 13.2 728 6.5 0.34
Medium MAP-CPT nanoparticle 1.0 16.6 2298 2.6 0.11
Long MAP-CPT nanoparticle 0.4 17.6 3636 1.7 0.07
Herceptin targeted MAP-CPT nanoparticle 0.2 21.2 2766 2.8 0.09
CPT41 - - 1.6 5538 156
Abbreviations: t1/2 α, redistribution half-life; t1/2 β, elimination half-life; AUC, area under curve; Vd, volume of distribution; Cl, systemic
clearance.
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Table 3
Treatment response for maximum tolerable dose (MTD) study
Dose (mg/kg)a Max % weight loss (day)b Death
Medium MAP 200 −1.1 (11) 0
NitroPBA-PEG polymer 200 −0.5 (2) 0
Short MAP-CPT nanoparticle
10 −4.5 (2) 0
15 −6.1 (10) 0
20 −10.2 (12) 0
Medium MAP-CPT nanoparticle
8 −6.8 (10) 0
10 −14.9 (12) 0
15 −18.4 (4) culledc
Long MAP-CPT nanoparticle
5 −4.8 (4) 0
8 −9.2 (12) 0
10 −16.5 (10) culledc
Herceptin targeted MAP-CPT nanoparticle
8 −5.2 (4) 0
10 −15.2 (9) culledc
aAll groups containing MAP-CPT are based on mg CPT/kg.
b
Maximum percent body weight loss.
cAnimals culled due to exceeding 15% body weight loss.
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Table 4
Antitumor efficacy studies in NCr nude mice bearing BT-474 xenograft tumors
Nbegin/Nend
a NTRD/NNTRD/Neuthan
b
Mean
tumor
volume
(mm3)
Median
tumor
volume
(mm3)
Nreg to zero
c P vs salined
MAP-CPT nanoparticle (8 mg/kg) 8/7 1/0/0 63 68 3 0.002
Irinotecan (80 mg/kg) 8/7 1/0/0 575 479 0 0.242
CPT (8 mg/kg) 8/0 4/0/4 808 417 0 0.781
Herceptin (5.9 mg/kg) 8/8 0/0/0 60 0 5 0.003
Herceptin targeted MAP-CPT
nanoparticle (1 mg CPT/kg, 5.9 mg
Herceptin equivalent/kg)
8/7 0/1/0 0 0 7 0.001
Herceptin (2.9 mg/kg) 6/6 0/0/0 278 245 2 0.026
Herceptin targeted MAP-CPT
nanoparticle (0.5 mg CPT/kg, 2.9 mg
Herceptin equivalent/kg)
6/6 0/0/0 141 187 2 0.005
Saline 8/0 0/0/8 911 1087 0 -
aNbegin is number of animals at beginning of study, Nend is number of animals surviving to end of study.
bNTRD is number of treatment-related death, NNTRD is number of non-treatment-related death, Neuthan is number of animals euthanized due to
exceeding tumor size limit of 1000 mm3.
cNreg to zero is number of animals with tumors regressed to zero at the end of study.
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